Web notes  

October 2017
PUBLICATIONS - Back

Oncology Archives

1. Connelly J, Benani DJ, Newman M, Burton B, Crow J, Levis M. Systemic effects of low-dose dopamine during administration of cytarabine. J Oncol Pharm Pract. 2016 Jul 5. pii: 1078155216656926. [Epub ahead of print]
Key words: cytarabine, dopamine, effects
http://www.ncbi.nlm.nih.gov/pubmed/27383219

2. Englert JM, Powell JD. Hunger pains: stimulating the appetite of the immune system for cancer. Cancer Cell. 2016 Jul 11;30(1):13-5. doi: 10.1016/j.ccell.2016.06.019.
Key words: appetite, hunger, cancer
http://www.ncbi.nlm.nih.gov/pubmed/27411584

3. Guo T, Gaykalova DA, Considine M, Wheelan S, Pallavajjala A, Bishop JA, Westra WH, Ideker T, Koch WM, Khan Z, Fertig EJ, Califano JA. Characterization of functionally active gene fusions in human papillomavirus related oropharyngeal squamous cell carcinoma. Int J Cancer. 2016 Jul 15;139(2):373-82. doi: 10.1002/ijc.30081. Epub 2016 Mar 30.
Key words: squamous, hpv, gene fusions, carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/26949921

4. Jiang RT, Schellenbacher C, Chackerian B, Roden RB. Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines. 2016 Jul;15(7):853-62. doi: 10.1586/14760584.2016.1157479.
Key words: hpv, vaccines, L2
http://www.ncbi.nlm.nih.gov/pubmed/26901354

5. Kaur H, Ali SZ, Huey L, Hütt-Cabezas M, Taylor I, Mao XG, Weingart M, Chu Q, Rodriguez FJ, Eberhart CG, Raabe EH. The transcriptional modulator HMGA2 promotes stemness and tumorigenicity in glioblastoma. Cancer Lett. 2016 Jul 10;377(1):55-64. doi: 10.1016/j.canlet.2016.04.020. Epub 2016 Apr 18.
Key words: glioblastoma, tumorigenicity, transcriptional
http://www.ncbi.nlm.nih.gov/pubmed/27102002

6. Markowski MC, Frick KD, Eshleman JR, Luo J, Antonarakis ES. Cost-savings analysis of AR-V7 testing in patients with metastatic castration-resistant prostate cancer eligible for treatment with abiraterone or enzalutamide. Prostate. 2016 Jul 12. doi: 10.1002/pros.23232. [Epub ahead of print]
Key words: enzalutamide, prostate cancer, abiraterone
http://www.ncbi.nlm.nih.gov/pubmed/27404039

7. Nadal R, Amin A, Geynisman DM, Voss MH, Weinstock M, Doyle J, Zhang Z, Viudez A, Plimack ER, McDermott DF, Motzer R, Rini B, Hammers HJ. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma. Ann Oncol. 2016 Jul;27(7):1304-11. doi: 10.1093/annonc/mdw160. Epub 2016 Apr 7.
Key words: VEGFR, treatment, cell death, carcinoma, renal
http://www.ncbi.nlm.nih.gov/pubmed/27059553

8. Rajeshkumar NV, Yabuuchi S, Pai SG, Tong Z, Hou S, Bateman S, Pierce DW, Heise C, Von Hoff DD, Maitra A, Hidalgo M. Superior therapeutic efficacy of nab-paclitaxel over cremophor based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Br J Cancer. 2016 Aug 9;115(4):442-453. doi: 10.1038/bjc.2016.215. Epub 2016 Jul 21.
Key words: pancreatic cancer, nab-paclitaxel, cremophor
http://www.ncbi.nlm.nih.gov/pubmed/27441498

9. Yang HY, Barbi J, Wu CY, Zheng Y, Vignali PD, Wu X, Tao JH, Park BV, Bandara S, Novack L, Ni X, Yang X, Chang KY, Wu RC, Zhang J, Yang CW, Pardoll DM, Li H, Pan F. MicroRNA-17 modulates regulatory T Cell function by targeting co-regulators of the Foxp3 transcription factor. Immunity. 2016 Jul 19;45(1):83 93. doi: 10.1016/j.immuni.2016.06.022.
Key words: Foxp3, T cell, regulatory
http://www.ncbi.nlm.nih.gov/pubmed/27438767

1. Alvarnas JC, Le Rademacher J, Wang Y, Little RF, Akpek G, Ayala E, Devine S, Baiocchi R, Lozanski G, Kaplan L, Noy A, Popat U, Hsu J, Morris LE Jr, Thompson J, Horowitz MH, Mendizabal A, Levine A, Krishnan A, Forman SJ, Navarro WH, Ambinder RF. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the (BMT CTN) 0803/(AMC) 071 Trial. Blood. 2016 Jun 13. pii: blood-2015-08-664706. [Epub ahead of print]
Key words: lymphoma, hematopoietic, HIV
http://www.ncbi.nlm.nih.gov/pubmed/27297790

2. Jacobson LA, Rane S, McReynolds LJ, Steppan DA, Chen AR, Paz-Priel I. Improved behavior and neuropsychological function in children with ROHHAD after high-dose cyclophosphamide. Pediatrics. 2016 Jul;138(1). pii: e20151080. doi: 10.1542/peds.2015-1080. Epub 2016 Jun 16.
Key words: cyclophosphamide, ROHHAD
http://www.ncbi.nlm.nih.gov/pubmed/27313069

3. Schweizer MT, Wang H, Luber B, Nadal R, Spitz A, Rosen DM, Cao H, Antonarakis ES, Eisenberger MA, Carducci MA, Paller C, Denmeade SR. Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: Results from the phase II BATMAN study. Prostate. 2016 Jun 24. doi: 10.1002/pros.23209. [Epub ahead of print]
Key words: androgen therapy, batman, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/27338150

4. Stearns V, Fackler MJ, Hafeez S, Lopez Bujanda Z, Chatterton RT, Jacobs LK, Khouri NF, Ivancic D, Kenney K, Shehata C, Jeter SC, Wolfman JA, Zalles CM, Huang P, Khan SA, Sukumar S. Gene methylation and cytological atypia in random fine needle aspirates for assessment of breast cancer risk. Cancer Prev Res (Phila). 2016 Jun 3. pii: canprevres.0377.2015. [Epub ahead of print]
Key words: breast cancer, cytological, methylation, atypia
http://www.ncbi.nlm.nih.gov/pubmed/27261491

5. Sternberg C, Armstrong A, Pili R, Ng S, Huddart R, Agarwal N, Khvorostenko D, Lyulko O, Brize A, Vogelzang N, Delva R, Harza M, Thanos A, James N, Werbrouck P, Bögemann M, Hutson T, Milecki P, Chowdhury S, Gallardo E, Schwartsmann G, Pouget JC, Baton F, Nederman T, Tuvesson H, Carducci M. Randomized, double-blind, placebo-controlled phase iii study of tasquinimod in men with metastatic castration-resistant prostate cancer. J Clin Oncol. 2016 Jun 13. pii: JCO669697. [Epub ahead of print]
Key words: prostate cancer, castration, tasquinimod
http://www.ncbi.nlm.nih.gov/pubmed/27298414

6. Thiele Orberg E, Fan H, Tam AJ, Dejea CM, Destefano Shields CE, Wu S, Chung L, Finard BB, Wu X, Fathi P, Ganguly S, Fu J, Pardoll DM, Sears CL, Housseau F. The myeloid immune signature of enterotoxigenic Bacteroides fragilis-induced murine colon tumorigenesis. Mucosal Immunol. 2016 Jun 15. doi: 10.1038/mi.2016.53. [Epub ahead of print]
Key words: murine, colon, tumorigenesis, enterotoxigenic
http://www.ncbi.nlm.nih.gov/pubmed/27301879

7. Zhang H, Liu T, Zhang Z, Payne SH, Zhang B, McDermott JE, Zhou JY, Petyuk VA, Chen L, Ray D, Sun S, Yang F, Chen L, Wang J, Shah P, Cha SW, Aiyetan P, Woo S, Tian Y, Gritsenko MA, Clauss TR, Choi C, Monroe ME, Thomas S, Nie S, Wu C, Moore RJ, Yu KH, Tabb DL, Fenyö D, Bafna V, Wang Y, Rodriguez H, Boja ES, Hiltke T, Rivers RC, Sokoll L, Zhu H, Shih IM, Cope L, Pandey A, Zhang B, Snyder MP, Levine
DA, Smith RD, Chan DW, Rodland KD; CPTAC Investigators. Integrated proteogenomic characterization of human high-grade serous ovarian cancer. Cell. 2016 Jun 28. pii: S0092-8674(16)30673-0. doi: 10.1016/j.cell.2016.05.069. [Epub ahead of print]
Key words: ovarian cancer, protogenomic, serous
http://www.ncbi.nlm.nih.gov/pubmed/27372738

1. Antonarakis ES, Armstrong AJ, Dehm SM, Luo J. Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting. Prostate Cancer Prostatic Dis. 2016 May 17. doi: 10.1038/pcan.2016.17. [Epub ahead of print] Review.
Key words: prostate cancer, targeting, androgen, receptor
http://www.ncbi.nlm.nih.gov/pubmed/27184811

2. Avtanski DB, Nagalingam A, Tomaszewski JE, Risbood P, Difillippantonio MJ, Saxena NK, Malhotra SV, Sharma D. Indolo-pyrido-isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53-miR34a axis. Mol Oncol. 2016 May 20. pii: S1574-7891(16)30018-7. doi: 10.1016/j.molonc.2016.04.003. [Epub ahead of print]
Key words: breast cancer, alkaloid, growth, invasion, inhibits
http://www.ncbi.nlm.nih.gov/pubmed/27259808

3. Childs EJ, Chaffee KG, Gallinger S, Syngal S, Schwartz AG, Cote ML, Bondy ML, Hruban RH, Chanock SJ, Hoover RN, Fuchs CS, Rider DN, Amundadottir LT, Stolzenberg-Solomon R, Wolpin BM, Risch HA, Goggins MG, Petersen GM, Klein AP. Association of common susceptibility variants of pancreatic cancer in higher risk patients: A PACGENE study. Cancer Epidemiol Biomarkers Prev. 2016 May 16. pii: cebp.1217.2015. [Epub ahead of print]
Key words: pancreatic cancer, susceptibility, common, variants
http://www.ncbi.nlm.nih.gov/pubmed/27197284

4. Murphy AG, Grossman SA. Acute hemolysis in a patient with a newly diagnosed glioblastoma. CNS Oncol. 2016 Jul;5(3):125-9.
Key words: hemolysis, glioblastoma
http://www.ncbi.nlm.nih.gov/pubmed/27230975

5. Sohal DP, Mangu PB, Khorana AA, Shah MA, Philip PA, O'Reilly EM, Uronis HE, Ramanathan RK, Crane CH, Engebretson A, Ruggiero JT, Copur MS, Lau M, Urba S, Laheru D. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2016 May 31. pii: JCO671412. [Epub ahead of print]
Key words: pancreatic cancer, guideline
http://www.ncbi.nlm.nih.gov/pubmed/27247222

6. Teo WW, Merino VF, Cho S, Korangath P, Liang X, Wu RC, Neumann NM, Ewald AJ, Sukumar S. HOXA5 determines cell fate transition and impedes tumor initiation and progression in breast cancer through regulation of E-cadherin and CD24. Oncogene. 2016 May 9. doi: 10.1038/onc.2016.95. [Epub ahead of print]
Key words: breast cancer, cell fate, progression, HOXA5
http://www.ncbi.nlm.nih.gov/pubmed/27157614

7. Wilky BA, Kim C, McCarty G, Montgomery EA, Kammers K, DeVine LR, Cole RN, Raman V, Loeb DM. RNA helicase DDX3: a novel therapeutic target in Ewing sarcoma. Oncogene. 2016 May 19;35(20):2574-83. doi: 10.1038/onc.2015.336.
Key words: Ewing, helicase, sarcoma, DDX3
http://www.ncbi.nlm.nih.gov/pubmed/26364611

1. Abdelfatah E, Guzzetta AA, Nagarajan N, Wolfgang CL, Pawlik TM, Choti MA, Schulick R, Montgomery EA, Meyer C, Thornton K, Herman J, Terezakis S, Frassica D, Ahuja N. Long-term outcomes in treatment of retroperitoneal sarcomas: A 15 year single-institution evaluation of prognostic features. J Surg Oncol. 2016 Apr 13. doi: 10.1002/jso.24256. [Epub ahead of print]
Key words: retroperitoneal, prognostic, sarcoma
http://www.ncbi.nlm.nih.gov/pubmed/27076350

2. Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, Partridge AH, Telli ML, Trudeau ME, Wolff AC. Selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for human epidermal growth factor receptor 2-positive breast cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline. J Clin Oncol. 2016 Apr 18. pii: JCO670182. [Epub ahead of print]
Key words: epidermal growth, chemotherapy, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/27091714

3. Denduluri N, Somerfield MR, Wolff AC. Selection of optimal adjuvant chemotherapy regimens for early breast cancer and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary. J Oncol Pract. 2016 Apr 26. pii: JOPR012344. [Epub ahead of print]
Key words: breast cancer, chemotherapy, Onatrio, HER-2
http://www.ncbi.nlm.nih.gov/pubmed/27118160

4. Ma HS, Greenblatt SM, Shirley CM, Duffield AS, Bruner JK, Li L, Nguyen B, Jung E, Aplan PD, Ghiaur G, Jones RJ, Small D. All-trans retinoic acid synergizes with FLT3 inhibition to eliminate FLT3/ITD+ leukemia stem cells in vitro and in vivo. Blood. 2016 Apr 21. pii: blood-2015-05-646786. [Epub ahead of print]
Key words: leukemia, stem cells, retinoic acid
http://www.ncbi.nlm.nih.gov/pubmed/27103744

5. Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Allgood VE, Carducci M. Mipsagargin, a novel thapsigargin-based PSMA-activated prodrug: results of a first-in-man phase I clinical trial in patients with refractory, advanced or metastatic solid tumours. Br J Cancer. 2016 Apr 26;114(9):986-94. doi: 10.1038/bjc.2016.72.
Key words: PSMA, solid tumours, metastatic
http://www.ncbi.nlm.nih.gov/pubmed/27115568

6. Silberstein JL, Taylor MN, Antonarakis ES. Novel insights into molecular indicators of response and resistance to modern androgen-axis therapies in prostate cancer. Curr Urol Rep. 2016 Apr;17(4):29. doi: 10.1007/s11934-016-0584-4.
Key words: molecular indicators, androgen, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/26902623

7. Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016 May;16(5):275-87. doi: 10.1038/nrc.2016.36. Epub 2016 Apr 15.
Key words: biomarkers, checkpoint, blockade, immune
http://www.ncbi.nlm.nih.gov/pubmed/27079802

8. Yoshida T, Jin K, Song H, Park S, Huso DL, Zhang Z, Liangfeng H, Zhu C, Bruchertseifer F, Morgenstern A, Sgouros G, Sukumar S. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer. Oncotarget. 2016 Apr 23. doi: 10.18632/oncotarget.8949. [Epub ahead of print]
Key words: ductal carcinoma, preclinical, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/27119227

1. Barakat DJ, Mendonca J, Barberi T, Zhang J, Kachhap SK, Paz-Priel I, Friedman AD. C/EBP? regulates sensitivity to bortezomib in prostate cancer cells by inducing REDD1 and autophagosome-lysosome fusion. Cancer Lett. 2016 May 28;375(1):152-61. doi: 10.1016/j.canlet.2016.03.005. Epub 2016 Mar 8.
Key words: bortezomib, REDD1, lysosome fusion
http://www.ncbi.nlm.nih.gov/pubmed/26968249

2. Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 2016 Mar 17. [Epub ahead of print] Review.
Key words: immunotherapy, epigenetic, combining
http://www.ncbi.nlm.nih.gov/pubmed/26988985

3. Cowan M, Springer S, Nguyen D, Taheri D, Guner G, Rodriguez MA, Wang Y, Kinde I, VandenBussche CJ, Olson MT, Cunha I, Fujita K, Ertoy D, Bivalacqua TJ, Kinzler K, Vogelstein B, Netto GJ, Papadopoulos N. High prevalence of TERT promoter mutations in primary squamous cell carcinoma of the urinary bladder. Mod Pathol. 2016 Mar 11. doi: 10.1038/modpathol.2016.53. [Epub ahead of print]
Key words: TERT, bladder, carcinoma, squamous
http://www.ncbi.nlm.nih.gov/pubmed/26965579

4. Goldstein SD, Trucco M, Guzman WB, Hayashi M, Loeb DM. A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget. 2016 Mar 31. doi: 10.18632/oncotarget.8522. [Epub ahead of print]
Key words: monoclonal, Wnt, osteosarcoma, antibody
http://www.ncbi.nlm.nih.gov/pubmed/27049730

5. Huo JS, Symons HJ, Robey N, Borowitz MJ, Schafer ES, Chen AR. Persistent multiyear control of relapsed T-Cell acute lymphoblastic leukemia with successive donor lymphocyte infusions: a case report. Pediatr Blood Cancer. 2016 Mar 14. doi: 10.1002/pbc.25971. [Epub ahead of print]
Key words: leukemia, infusions, infusions, multiyear
http://www.ncbi.nlm.nih.gov/pubmed/26990138

6. Teply BA, Antonarakis ES. Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes. 2016 Mar 14. [Epub ahead of print]
Key words: prostate cancer, androgen, axis blockade
http://www.ncbi.nlm.nih.gov/pubmed/26978733

1. Akinboye ES, Brennen WN, Rosen DM, Bakare O, Denmeade SR. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy. Prostate. 2016 Feb 2. doi: 10.1002/pros.23162. [Epub ahead of print]
Key words: emetine, enzymatic, fibroblast, peptidase
http://www.ncbi.nlm.nih.gov/pubmed/26835873

2. Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, Dubois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley CE, Brown PA. A Phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study. Clin Cancer Res. 2016 Feb 26. pii: clincanres.1998.2015. [Epub ahead of print]
Key words: leukemia, lymphoma, quizartinib
http://www.ncbi.nlm.nih.gov/pubmed/26920889

3. Faisal F, Tsai HL, Blackford A, Olino K, Xia C, De Jesus-Acosta A, Le DT, Cosgrove D, Azad N, Rasheed Z, Diaz LA Jr, Donehower R, Laheru D, Hruban RH, Fishman EK, Edil BH, Schulick R, Wolfgang C, Herman J, Zheng L. Longer course of induction chemotherapy followed by chemoradiation favors better survival outcomes for patients with locally advanced pancreatic cancer. Am J Clin Oncol. 2016 Feb;39(1):18-26. doi: 10.1097/COC.0000000000000022.
Key words: pancreatic cancer, chemoradiation, survival, chemotherapy
http://www.ncbi.nlm.nih.gov/pubmed/24351782

4. Fu T, Pappou EP, Guzzetta AA, Calmon Mde F, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. IGFBP-3 gene methylation in primary tumor predicts recurrence of stage ii colorectal cancers. Ann Surg. 2016 Feb;263(2):337-44. doi: 10.1097/SLA.0000000000001204.
Key words: colorectal cancer, methylation
http://www.ncbi.nlm.nih.gov/pubmed/25822686

5. Housseau F, Wu S, Wick EC, Fan H, Wu X, Llosa NJ, Smith KN, Tam A, Ganguly S, Wanyiri JW, Iyadorai T, Malik AA, Roslani AC, Vadivelu JS, Van Meerbeke S, Huso DL, Pardoll DM, Sears CL. Redundant innate and adaptive sources of IL-17 production drive colon tumorigenesis. Cancer Res. 2016 Feb 15. pii: canres.0749.2015. [Epub ahead of print]
Key words: colon, redundant, tumorigenesis
http://www.ncbi.nlm.nih.gov/pubmed/26880802

6. Izumchenko E, Meir J, Bedi A, Wysocki PT, Hoque M, Sidransky D. Patient derived xenografts as tools in pharmaceutical development. Clin Pharmacol Ther. 2016 Feb 13. doi: 10.1002/cpt.354. [Epub ahead of print]
Key words: xenografts, pharmaceutical development
http://www.ncbi.nlm.nih.gov/pubmed/26874468

7. Jhaveri DT, Kim MS, Thompson ED, Huang L, Sharma R, Klein AP, Zheng L, Le DT, Laheru DA, Pandey A, Jaffee EM, Anders RA. Using quantitative seroproteomics to identify antibody biomarkers in pancreatic cancer. Cancer Immunol Res. 2016 Mar;4(3):225-33. doi: 10.1158/2326-6066.CIR-15-0200-T. Epub 2016 Feb 3.
Key words: seroproteomics, pancreatic cancer, antibodies
http://www.ncbi.nlm.nih.gov/pubmed/26842750

8. Long SY, Latimer EM, Hayward GS. Review of elephant endotheliotropic herpesviruses and acute hemorrhagic disease. ILAR J. 2016 Feb 24;56(3):283-96. doi: 10.1093/ilar/ilv041.
Key words: herpesviruses, elephant, hemorrhagic
PubMed PMID: 26912715; PubMed Central PMCID: PMC4765743.
http://www.ncbi.nlm.nih.gov/pubmed/26912715

9. Roberts NJ, Norris AL, Petersen GM, Bondy ML, Brand R, Gallinger S, Kurtz RC, Olson SH, Rustgi AK, Schwartz AG, Stoffel E, Syngal S, Zogopoulos G, Ali SZ, Axilbund J, Chaffee KG, Chen YC, Cote ML, Childs EJ, Douville C, Goes FS, Herman JM, Iacobuzio-Donahue C, Kramer M, Makohon-Moore A, McCombie RW, McMahon KW, Niknafs N, Parla J, Pirooznia M, Potash JB, Rhim AD, Smith AL, Wang Y, Wolfgang CL, Wood LD, Zandi PP, Goggins M, Karchin R, Eshleman JR, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH, Klein AP. Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer. Cancer Discov. 2016 Feb;6(2):166-75. doi: 10.1158/2159-8290.CD-15-0402. Epub 2015 Dec 9.
Key words: pancreatic cancer, familial, sequencing, genome
http://www.ncbi.nlm.nih.gov/pubmed/26658419

10 Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NZ, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). Oncotarget. 2016 Feb 17. doi: 10.18632/oncotarget.7436. [Epub ahead of print]
Key words: pancreatic cancer, recurrence, immunohistochemistry
http://www.ncbi.nlm.nih.gov/pubmed/26894863

1. Armstrong AJ, Halabi S, Healy P, Lee WR, Koontz BF, Moul JW, Mundy K, Creel P, Wood S, Davis K, Carducci MA, Stein M, Hobbs C, Reimer B, Nguyen M, Anand M, Bratt L, Kim S, Tran PT, George DJ; Department of Defense Prostate Cancer Clinical Trials Consortium (DOD PCCTC). A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy. Prostate Cancer Prostatic Dis. 2016 Mar;19(1):100-6. doi: 10.1038/pcan.2015.59. Epub 2016 Jan 12.
Key words: docetaxel, prednisone, prostatectomy, radiation
http://www.ncbi.nlm.nih.gov/pubmed/26754260

2. Brennen WN, Kisteman LN, Isaacs JT. Rapid selection of mesenchymal stem and progenitor cells in primary prostate stromal cultures. Prostate. 2016 Jan 6. doi: 10.1002/pros.23145. [Epub ahead of print]
Key words: stromal, progenitor, mesenchymal
http://www.ncbi.nlm.nih.gov/pubmed/26732992

3. Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, Christenson ES, Medford A, Mattox A, De Marzo AM, Argani P, Chawla A, Hurley PJ, Lauring J, Park BH. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. 2016 Jan 28. doi: 10.18632/oncotarget.7057. [Epub ahead of print]
Key words: Ki-67, stem cells, proliferation
http://www.ncbi.nlm.nih.gov/pubmed/26823390

4. Leong WY, Guo H, Ma O, Huang H, Cantor AB, Friedman AD. Runx1 Phosphorylation by Src Increases Trans-activation via Augmented Stability, Reduced Histone Deacetylase (HDAC) Binding, and Increased DNA Affinity, and Activated Runx1 Favors Granulopoiesis. J Biol Chem. 2016 Jan 8;291(2):826-36. doi: 10.1074/jbc.M115.674234. Epub 2015 Nov 23.
Key words: deacetylase, phosphorylation, granulopoiesis
http://www.ncbi.nlm.nih.gov/pubmed/26598521

5. Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, Han L, Foster YM, Zhou XC, Zhang Z, Connolly R, Stearns V, Ali SZ, Adams C, Chen Q, Pan D, Huso DL, Ordentlich P, Brodie A, Sukumar S. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple negative breast cancer. Cancer Res. 2016 Jan 19. pii: canres.1619.2015. [Epub ahead of print]
Key words: breast cancer, triple negative, initiating, combined
http://www.ncbi.nlm.nih.gov/pubmed/26787836

6. Reiss KA, Rangachari D, Cosgrove D, Wilky B, Donehower R. Growing pains: a simulation-based curriculum for improving the transition to hematology/oncology fellowship. J Cancer Educ. 2016 Jan 15. [Epub ahead of print]
Key words: transition, improving, curriculum, fellowship
http://www.ncbi.nlm.nih.gov/pubmed/26768145

7. Strowd RE, Abuali I, Ye X, Lu Y, Grossman SA. The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide. J Neurooncol. 2016 Jan 4. [Epub ahead of print]
Key words: temozolomide, astrocytoma, survival
http://www.ncbi.nlm.nih.gov/pubmed/26729269

8.Thompson E, Taube JM, Elwood H, Sharma R, Meeker A, Warzecha HN, Argani P, Cimino-Mathews A, Emens LA. The immune microenvironment of breast ductal carcinoma in situ. Mod Pathol. 2016 Jan 15. doi: 10.1038/modpathol.2015.158. [Epub ahead of print]
Key words: microenvironment, breast cancer, ductal carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/26769139

1. Chung CH, Rudek MA, Kang H, Marur S, John P, Tsottles N, Bonerigo S, Veasey A, Kiess A, Quon H, Cmelak A, Murphy BA, Gilbert J. A phase I study afatinib/carboplatin/paclitaxel induction chemotherapy followed by standard chemoradiation in HPV-negative or high-risk HPV-positive locally advanced stage III/IVa/IVb head and neck squamous cell carcinoma. Oral Oncol. 2016 Feb;53:54-9. doi: 10.1016/j.oraloncology.2015.11.020. Epub 2015 Dec 17.
Key words: ABCB1; Afatinib; Carboplatin; Efficacy; Head and neck squamous cell carcinoma; Paclitaxel; Phase I trial; Toxicity
http://www.ncbi.nlm.nih.gov/pubmed/26705063

2. Karp JE, Wolff AC. Cancer susceptibility genes and their potential implication regarding systemic therapy for early-stage breast cancer. Cancer. 2016 Jan 15;122(2):178-180. doi: 10.1002/cncr.29613. Epub 2015 Dec 7.
Key words: breast cancer, genes, systemic therapy
http://www.ncbi.nlm.nih.gov/pubmed/26642256

3. Murtola T, Gurel B, Umbehr M, Lucia MS, Thompson IM Jr, Goodman PJ, Kristal AR, Parnes HL, Lippman SM, Sutcliffe S, Peskoe SB, Barber JR, Drake CG, Nelson WG, De Marzo AM, Platz EA. Inflammation in benign prostate tissue and prostate cancer in the finasteride arm of the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2015 Dec 29. pii: cebp.0987.2015. [Epub ahead of print]
Key words: prostate cancer, finasteride
http://www.ncbi.nlm.nih.gov/pubmed/26715424

4. Sutcliffe S, Nevin RL, Pakpahan R, Elliott DJ, Langston ME, De Marzo AM, Gaydos CA, Isaacs WB, Nelson WG, Sokoll LJ, Walsh PC, Zenilman JM, Cersovsky SB, Platz EA. Infectious mononucleosis, other infections, and prostate-specific antigen concentration as a marker of prostate involvement during infection. Int J Cancer. 2015 Dec 17. doi: 10.1002/ijc.29966. [Epub ahead of print]
Key words: Infectious mononucleosis; epidemiology; infection; prostate cancer; prostate-specific antigen
http://www.ncbi.nlm.nih.gov/pubmed/26678984

5. Wong HY, Wang GM, Croessmann S, Zabransky DJ, Chu D, Garay JP, Cidado J, Cochran RL, Beaver JA, Aggarwal A, Liu ML, Argani P, Meeker A, Hurley PJ, Lauring J, Park BH. TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. Oncotarget. 2015 Dec 23. doi:10.18632/oncotarget.6743. [Epub ahead of print]
Key words: TMSB4Y; Y chromosome; cancer genetics; male breast cancer; tumor suppressor
http://www.ncbi.nlm.nih.gov/pubmed/26702755

6. Zong JC, Heaggans SY, Long SY, Latimer EM, Nofs SA, Bronson E, Casares M, Fouraker MD, Pearson VR, Richman LK, Hayward GS. Detection of quiescent infections with multiple elephant endotheliotropic Herpesviruses EEHV2, EEHV3, EEHV6 and EEHV7 within lymphoid lung nodules or lung and spleen tissue samples from five asymptomatic adult African elephants. J Virol. 2015 Dec 30. pii: JVI.02936-15. [Epub ahead of print]
Key words: endotheliotropic Herpesviruses, lung nodules, lung tissue, spleen tissue, elephant
http://www.ncbi.nlm.nih.gov/pubmed/26719245

1. Noonan KA, Borrello IM. Marrow infiltrating lymphocytes: their role in adoptive immunotherapy. Cancer J. 2015 Nov-Dec;21(6):501-5. doi: 10.1097/PPO.0000000000000159.
Key words: lymphocytes, immunotherapy, marrow
http://www.ncbi.nlm.nih.gov/pubmed/26588683

2. Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2. Oncogene. 2015 Nov 26;34(48):5869-78. doi: 10.1038/onc.2015.38. Epub 2015 Mar 9.
Key words: lung cancer, EZH2, methylation
http://www.ncbi.nlm.nih.gov/pubmed/25746006

3. Rudek MA, Graham RA, Ratain MJ. Harmonization of renal function assessment is needed during early clinical development of oncology drugs. J Clin Oncol. 2015 Nov 30. pii: JCO642553. [Epub ahead of print]
Key words: harmonization, development, assessment
http://www.ncbi.nlm.nih.gov/pubmed/26628472

4. Schweizer MT, Antonarakis ES. Liquid biopsy: Clues on prostate cancer drug resistance. Sci Transl Med. 2015 Nov 4;7(312):312fs45. doi: 10.1126/scitranslmed.aad4008.
Key words: prostate cancer, drug resistance
http://www.ncbi.nlm.nih.gov/pubmed/26537254

5. Tao JH, Barbi J, Pan F. Hypoxia-inducible factors in T lymphocyte differentiation and function. A review in the theme: cellular responses to hypoxia. Am J Physiol Cell Physiol. 2015 Nov 1;309(9):C580-9. doi: 10.1152/ajpcell.00204.2015. Epub 2015 Sep 9.
Key words: lymphocyte, cellular responses, hypoxia
http://www.ncbi.nlm.nih.gov/pubmed/26354751

6. Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, Weiss M, Li M, De Jesus-Acosta A, Wolfgang CL, Zheng L. Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. Oncotarget. 2015 Nov 3;6(34):36903-10. doi: 10.18632/oncotarget.5054.
Key words: pancreatic, recurrence, adenocarcinoma, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/26372811

7. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14. doi: 10.1073/pnas.1516853112. Epub 2015 Oct 27.
Key words: signaling, missense, mutations, HER2
http://www.ncbi.nlm.nih.gov/pubmed/26508629

8. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? Am J Hematol. 2015 Nov;90(11):1036-40. doi: 10.1002/ajh.24173.
Key words: stratifying models, myelodysplastic, prognostic value
http://www.ncbi.nlm.nih.gov/pubmed/26284571

1. Amankwah EK, Saenz AM, Hale GA, Brown PA. Association between body mass index at diagnosis and pediatric leukemia mortality and relapse: a systematic review and meta-analysis. Leuk Lymphoma. 2015 Oct 9:1-9. [Epub ahead of print]
Key words: lymphoma, pediatric mortality
http://www.ncbi.nlm.nih.gov/pubmed/26453440

2. Avtanski DB, Nagalingam A, Bonner MY, Arbiser JL, Saxena NK, Sharma D. Honokiol activates LKB1-miR-34a axis and antagonizes the oncogenic actions of leptin in breast cancer. Oncotarget. 2015 Oct 6;6(30):29947-62. doi: 10.18632/oncotarget.4937.
Key words: leptin, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/26359358

3. Ambady P, Holdhoff M, Bonekamp D, Wong F, Grossman SA. Late relapses in primary CNS lymphoma after complete remissions with high-dose methotrexate monotherapy. CNS Oncol. 2015 Oct 28. [Epub ahead of print]
Key words: relapses, lymphoma, methotrexate
http://www.ncbi.nlm.nih.gov/pubmed/26507609

4. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
Key words: lung cancer, nivolumab, docetaxel, nonsquamous
http://www.ncbi.nlm.nih.gov/pubmed/26412456

5. Bertotti A, Papp E, Jones S, Adleff V, Anagnostou V, Lupo B, Sausen M, Phallen J, Hruban CA, Tokheim C, Niknafs N, Nesselbush M, Lytle K, Sassi F, Cottino F, Migliardi G, Zanella ER, Ribero D, Russolillo N, Mellano A, Muratore A, Paraluppi G, Salizzoni M, Marsoni S, Kragh M, Lantto J, Cassingena A, Li QK, Karchin R, Scharpf R, Sartore-Bianchi A, Siena S, Diaz LA Jr, Trusolino L, Velculescu VE. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature. 2015 Oct 8;526(7572):263-7. doi: 10.1038/nature14969. Epub 2015 Sep 30.
Key words: EGFR, landscape, colorectal cancer

http://www.ncbi.nlm.nih.gov/pubmed/26416732

6. Cooper SL, Arceci RJ, Gamper CJ, Teachey DT, Schafer ES. Successful Treatment of Recurrent Autoimmune Cytopenias in the Context of Sinus Histiocytosis With Massive Lymphadenopathy Using Sirolimus. Pediatr Blood Cancer. 2015 Oct 9. doi: 10.1002/pbc.25770. [Epub ahead of print]
Key words: cytopenias, sirolimus, treatment, autoimmune
http://www.ncbi.nlm.nih.gov/pubmed/26452062

7. Gaykalova DA, Manola JB, Ozawa H, Zizkova V, Morton K, Bishop JA, Sharma R, Zhang C, Michailidi C, Considine M, Tan M, Fertig EJ, Hennessey PT, Ahn J, Koch WM, Westra WH, Khan Z, Chung CH, Ochs MF, Califano JA. NF-?B and stat3 transcription factor signatures differentiate HPV-positive and HPV-negative head and neck squamous cell carcinoma. Int J Cancer. 2015 Oct 15;137(8):1879-89. doi: 10.1002/ijc.29558. Epub 2015 Jun 23.
Key words: carcinoma, stat3, squamous, transcription
http://www.ncbi.nlm.nih.gov/pubmed/25857630

8. Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, Isaacs SD, Berman DM, Rider JR, Jordahl KM, Mucci LA, Huang J, An S, Park BH, Isaacs WB, Marchionni L, Ross AE, Schaeffer E. Germline variants in asporin vary by race, modulate the tumor microenvironment and are differentially associated with metastatic prostate cancer. Clin Cancer Res. 2015 Oct 7. pii: clincanres.0256.2015. [Epub ahead of print]
Key words: prostate cancer, microenvironment, modulate
http://www.ncbi.nlm.nih.gov/pubmed/26446945

9. Negi SS, Brown P. Transient rRNA synthesis inhibition with CX-5461 is sufficient to elicit growth arrest and cell death in acute lymphoblastic leukemia cells. Oncotarget. 2015 Oct 27;6(33):34846-58. doi: 10.18632/oncotarget.5413.
Key words: leukemia, synthesis, rRNA, transient
http://www.ncbi.nlm.nih.gov/pubmed/26472108

10. Qualliotine JR, Mydlarz WK, Chan JY, Zhou X, Wang H, Agrawal N. Comparing staging by positron emission tomography with contrast-enhanced computed tomography and by pathology in head and neck squamous cell carcinoma. J Laryngol Otol. 2015 Oct 22:1-7. [Epub ahead of print]
Key words: tomography, carcinoma, squamous, positron
http://www.ncbi.nlm.nih.gov/pubmed/26490394

11. Soares KC, Rucki AA, Kim V, Foley K, Solt S, Wolfgang CL, Jaffee EM, Zheng L. TGF-? blockade depletes T regulatory cells from metastatic pancreatic tumors in a vaccine dependent manner. Oncotarget. 2015 Oct 15. doi: 10.18632/oncotarget.5656. [Epub ahead of print]
Key words: pancreatic tumors, vaccine
http://www.ncbi.nlm.nih.gov/pubmed/26515728

12. Wu X, Zahari MS, Ma B, Liu R, Renuse S, Sahasrabuddhe NA, Chen L, Chaerkady R, Kim MS, Zhong J, Jelinek C, Barbhuiya MA, Leal-Rojas P, Yang Y, Kashyap MK, Marimuthu A, Ling M, Fackler MJ, Merino V, Zhang Z, Zahnow CA, Gabrielson E, Stearns V, Roa JC, Sukumar S, Gill PS, Pandey A. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways. Oncotarget. 2015 Oct 6;6(30):29143-60. doi: 10.18632/oncotarget.5020.
Key words: phosphotyrosine, breast cancer, tyrosine kynase
http://www.ncbi.nlm.nih.gov/pubmed/26356563

13. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015 Nov 10;112(45):E6205-14. doi: 10.1073/pnas.1516853112. Epub 2015 Oct 27.
Key words: mutations, signaling, missense, oncogenic
http://www.ncbi.nlm.nih.gov/pubmed/26508629

14. Zeidan AM, Sekeres MA, Garcia-Manero G, Steensma DP, Zell K, Barnard J, Al Ali N, Zimmerman C, Roboz G, DeZern A, Nazha A, Jabbour E, Kantarjian H, Gore SD, Maciejewski JP, List A, Komrokji R. Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides. Leukemia. 2015 Oct 14. doi: 10.1038/leu.2015.283. [Epub ahead of print]
Key words: leukemia, stratification
http://www.ncbi.nlm.nih.gov/pubmed/26464171

15. Zhu W, Huang P, Macura KJ, Artemov D. Association between breast cancer, breast density, and body adiposity evaluated by MRI. Eur Radiol. 2015 Oct 21. [Epub ahead of print]
Key words: adiposity, breast cancer, density
http://www.ncbi.nlm.nih.gov/pubmed/26489749

1. Beachler DC, Guo Y, Xiao W, Burk RD, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Sugar EA, Reddy S, Gillison ML, D'Souza G. High oral human papillomavirus type 16 load predicts long-term persistence in individuals with or at risk for HIV infection. J Infect Dis. 2015 Nov 15;212(10):1588-91. doi: 10.1093/infdis/jiv273.
Key words: persistence, hpv, infections, HIV
http://www.ncbi.nlm.nih.gov/pubmed/25954049

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhäufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crinò L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643.
Key words: lung cancer, docetaxel, nonsquamous
http://www.ncbi.nlm.nih.gov/pubmed/26412456

3. Cosgrove DP, Reyes DK, Pawlik TM, Feng AL, Kamel IR, Geschwind JF. Open-label single-arm phase ii trial of sorafenib therapy with drug-eluting bead transarterial chemoembolization in patients with unresectable hepatocellular carcinoma: clinical results. Radiology. 2015 Nov;277(2):594-603. doi:
10.1148/radiol.2015142481.
Key words: carcinoma, hepatocellular, chemoembolization
http://www.ncbi.nlm.nih.gov/pubmed/26069923

4. Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, Francica BJ, Elias J, Daniels A, Dubensky TW Jr, Lauer P, Brockstedt D, Baxi EG, Calabresi PA, Taube JM, Pardo CA, Brem H, Pardoll DM, Lim M, Drake CG. Systemic tolerance mediated by melanoma brain tumors is reversible by radiotherapy and vaccination. Clin Cancer Res. 2015 Oct 21. pii: clincanres.1516.2015.
Key words: vaccination, radiotherapy, brain tumor, reversible, melanoma
http://www.ncbi.nlm.nih.gov/pubmed/26490306

5. Li R, Faden DL, Fakhry C, Langelier C, Jiao Y, Wang Y, Wilkerson MD, Pedamallu CS, Old M, Lang J, Loyo M, Ahn SM, Tan M, Gooi Z, Chan J, Richmon J, Wood LD, Hruban RH, Bishop J, Westra WH, Chung CH, Califano J, Gourin CG, Bettegowda C, Meyerson M, Papadopoulos N, Kinzler KW, Vogelstein B, DeRisi JL, Koch WM, Agrawal N. Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck. 2015 Nov;37(11):1642-9. doi: 10.1002/hed.23807. Key words: metagenomics, squamous, smoke, tongue, carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/24954188

6. Lombardi LR, Kanakry CG, Zahurak M, Durakovic N, Bolaños-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2015 Oct 12:1-10. [Epub ahead of print]
Key words: cyclophosphamide, busulfan
http://www.ncbi.nlm.nih.gov/pubmed/26292764

7. Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate. 2015 Nov;75(15):1814-20. doi: 10.1002/pros.23064.
Key words: prostate cancer, abiraterone, docetaxel
http://www.ncbi.nlm.nih.gov/pubmed/26306637

8. Santa-Maria CA, Blackford AL, Nguyen AT, Skaar TC, Philips S, Oesterreich S, Rae JM, Desta Z, Robarge JD, Henry NL, Storniolo AM, Hayes DF, Blumenthal RS, Ouyang P, Post WS, Flockhart DA, Stearns V. Association of variants in candidate genes with lipid profiles in women with early breast cancer on adjuvant aromatase inhibitor therapy. Clin Cancer Res. 2015 Oct 13. pii: clincanres.1213.2015. [Epub ahead of print]
Key words: lipid profiles, breast cancer, aromatase
http://www.ncbi.nlm.nih.gov/pubmed/26463708

9. Sison EA, Magoon D, Li L, Annesley CE, Romagnoli B, Douglas GJ, Tuffin G, Zimmermann J, Brown P. POL5551, a novel and potent CXCR4 antagonist, enhances sensitivity to chemotherapy in pediatric ALL. Oncotarget. 2015 Oct 13;6(31):30902-18. doi: 10.18632/oncotarget.5094.
Key words: CXCR4, chemotherapy, pediatric
http://www.ncbi.nlm.nih.gov/pubmed/26360610

10. Romano A, Parrinello NL, Consoli ML, Marchionni L, Forte S, Conticello C, Pompa A, Corso A, Milone G, Di Raimondo F, Borrello I. Neutrophil to lymphocyte ratio (NLR) improves the risk assessment of ISS staging in newly diagnosed MM patients treated upfront with novel agents. Ann Hematol. 2015 Nov;94(11):1875-83. doi: 10.1007/s00277-015-2462-4. Epub 2015 Jul 31.
Key words: ISS, multiple myeloma, neutrophil
http://www.ncbi.nlm.nih.gov/pubmed/26223359

11. Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, Erlanger B, Parsons HA, Manto KM, Bose R, Lauring J, Arteaga CL, Konstantopoulos K, Park BH. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015 Oct
27. pii: 201516853. [Epub ahead of print]
Key words: oncogenic signaling, mutations, HER2
http://www.ncbi.nlm.nih.gov/pubmed/26508629

12. Zeidan AM, Sekeres MA, Wang XF, Al Ali N, Garcia-Manero G, Steensma DP, Roboz G, Barnard J, Padron E, DeZern A, Maciejewski JP, List AF, Komrokji RS; MDS Clinical Research Consortium (Funded by Edward P. Evans Foundation). Comparing the prognostic value of risk stratifying models for patients with lower-risk myelodysplastic syndromes: Is one model better? Am J Hematol. 2015
Nov;90(11):1036-40. doi: 10.1002/ajh.24173.
Key words: myelodysplastic, stratifying
http://www.ncbi.nlm.nih.gov/pubmed/26284571

1. Ball DW, Jin N, Xue P, Bhan S, Ahmed SR, Rosen DM, Schayowitz A, Clark DP, Nelkin BD. Trametinib with and without pazopanib has potent preclinical activity in thyroid cancer. Oncol Rep. 2015 Aug 26. doi: 10.3892/or.2015.4225. [Epub ahead of print]
Key words: thyroid cancer, pazopanib, trametinib
http://www.ncbi.nlm.nih.gov/pubmed/26324075

2. Cabanillas ME, Schlumberger M, Jarzab B, Martins RG, Pacini F, Robinson B, McCaffrey JC, Shah MH, Bodenner DL, Topliss D, Andresen C, O'Brien JP, Ren M, Funahashi Y, Allison R, Elisei R, Newbold K, Licitra LF, Sherman SI, Ball DW. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer. 2015 Aug 15;121(16):2749-56. doi: 10.1002/cncr.29395. Epub 2015 Apr 24.
Key words: thyroid cancer, lenvatinib, radioiodine
http://www.ncbi.nlm.nih.gov/pubmed/25913680

3. Croessmann S, Wong HY, Zabransky DJ, Chu D, Mendonca J, Sharma A, Mohseni M, Rosen DM, Scharpf RB, Cidado J, Cochran RL, Parsons HA, Dalton WB, Erlanger B, Button B, Cravero K, Kyker-Snowman K, Beaver JA, Kachhap S, Hurley PJ, Lauring J, Park BH. NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proc Natl Acad Sci U S A. 2015 Aug 31. pii: 201503683.
Key words: homeostasis, centrosome, p53
http://www.ncbi.nlm.nih.gov/pubmed/26324937

4. Gorin MA, Rowe SP, Allaf ME, Argani P. Angiomyolipoma with epithelial cysts: Add one to the differential of cystic renal lesions. Int J Urol. 2015 Aug 25. doi: 10.1111/iju.12908. [Epub ahead of print]
Key words: epithelial, renal, cysts, lesions
http://www.ncbi.nlm.nih.gov/pubmed/26303457

5. Haffner MC, Weier C, Xu M, Vaghasia A, Gürel B, Gümü?kaya B, Esopi DM, Fedor H, Tan HL, Kulac I, Hicks J, Isaacs WB, Lotan TL, Nelson WG, Yegnasubramanian S, De Marzo AM. Molecular evidence that invasive adenocarcinoma can mimic prostatic intraepithelial neoplasia (PIN) and intraductal carcinoma through retrograde glandular colonization. J Pathol. 2015 Aug 31. doi: 10.1002/path.4628. [Epub ahead of print]
Key words: adenocarcinoma, glandular, retrograde, colonization
http://www.ncbi.nlm.nih.gov/pubmed/26331372

6. Hurley PJ, Hughes RM, Simons B, Huang J, Miller RM, Shinder B, Haffner MC, Esopi D, Kinura Y, Jabbari J, Ross AE, Erho N, Vergara IA, Faraj SF, Davicioni E, Netto GJ, Yegnasubramanian S, An S, Schaeffer E. Androgen Regulated SPARCL1 in the Tumor Microenvironment Inhibits Metastatic Progression. Cancer Res. 2015 Aug 20. pii: canres.0024.2015. [Epub ahead of print]
Key words: SPARCL1, microenvironment
http://www.ncbi.nlm.nih.gov/pubmed/26294211

7. Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2015 Aug 25. doi: 10.1038/nrclinonc.2015.128. [Epub ahead of print] Review.
Key words: haploidentical, HLA, transplantation
http://www.ncbi.nlm.nih.gov/pubmed/26305035

8. Lombardi LR, Kanakry C, Zahurak M, Durakovic N, Bolaños-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma. 2015 Aug 21:1-30. [Epub ahead of print]
Key words: busulfan, cyclophosphamide
http://www.ncbi.nlm.nih.gov/pubmed/26292764

9. Maughan BL, Xhou XC, Suzman DL, Nadal R, Bassi S, Schweizer MT, Antonarakis ES. Optimal sequencing of docetaxel and abiraterone in men with metastatic castration-resistant prostate cancer. Prostate. 2015 Aug 26. doi: 10.1002/pros.23064. [Epub ahead of print]
Key words: prostate cancer, abiraterone, docetaxel
http://www.ncbi.nlm.nih.gov/pubmed/26306637

10. Platz EA, Drake CG, Wilson KM, Sutcliffe S, Kenfield SA, Mucci LA, Stampfer MJ, Willett WC, Camargo CA Jr, Giovannucci E. Asthma and risk of lethal prostate cancer in the Health Professionals Follow-Up Study. Int J Cancer. 2015 Aug 15;137(4):949-58. doi: 10.1002/ijc.29463. Epub 2015 Feb 27.
Key words: prostate cancer, asthma
http://www.ncbi.nlm.nih.gov/pubmed/25648070

11. Tao JJ, Visvanathan K, Wolff AC. Long term side effects of adjuvant chemotherapy in patients with early breast cancer. Breast. 2015 Aug 20. pii: S0960-9776(15)00173-3. doi: 10.1016/j.breast.2015.07.035. [Epub ahead of print]
Key words: breast cancer, chemotherapy, side effects
http://www.ncbi.nlm.nih.gov/pubmed/26299406

1. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncol. 2015 Aug 1;1(5):582-591. doi: 10.1001/jamaoncol.2015.1341.
Key words: prostate cancer, chemotherapy, taxane
http://www.ncbi.nlm.nih.gov/pubmed/26181238

2. Chen D, Nicholas J. Promotion of endoplasmic reticulum-associated degradation of procathepsin D by human Herpesvirus 8-encoded viral interleukin-6. J Virol. 2015 Aug 1;89(15):7979-90. doi: 10.1128/JVI.00375-15. Epub 2015 May 27.
Key words: herpesvirus, interleukin
http://www.ncbi.nlm.nih.gov/pubmed/26018151

3. Childs EJ, Mocci E, Campa D, Bracci PM, Gallinger S, Goggins M, Li D, Neale RE, Olson SH, Scelo G, Amundadottir LT, Bamlet WR, Bijlsma MF, Blackford A, Borges M, Brennan P, Brenner H, Bueno-de-Mesquita HB, Canzian F, Capurso G, Cavestro GM, Chaffee KG, Chanock SJ, Cleary SP, Cotterchio M, Foretova L, Fuchs C, Funel N, Gazouli M, Hassan M, Herman JM, Holcatova I, Holly EA, Hoover RN, Hung RJ, Janout V, Key TJ, Kupcinskas J, Kurtz RC, Landi S, Lu L, Malecka-Panas E, Mambrini A, Mohelnikova-Duchonova B, Neoptolemos JP, Oberg AL, Orlow I, Pasquali C, Pezzilli R, Rizzato C, Saldia A, Scarpa A, Stolzenberg-Solomon RZ, Strobel O, Tavano F, Vashist YK, Vodicka P, Wolpin BM, Yu H, Petersen GM, Risch HA, Klein AP. Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nat Genet. 2015 Aug;47(8):911-6. doi: 10.1038/ng.3341. Epub 2015 Jun 22.
Key words: pancreatic cancer, 1p13, 3q29, 17q25
http://www.ncbi.nlm.nih.gov/pubmed/26098869

4. Geis AL, Fan H, Wu X, Wu S, Huso DL, Wolfe JL, Sears CL, Pardoll DM, Housseau F. Regulatory T cell response to enterotoxigenic Bacteroides fragilis colonization triggers IL-17-dependent colon carcinogenesis. Cancer Discov. 2015 Jul 22. pii: CD-15-0447. [Epub ahead of print]
Key words: colon, enterotoxigenic, bacteroides fragilis
http://www.ncbi.nlm.nih.gov/pubmed/26201900

5. Korangath P, Teo WW, Sadik H, Han L, Mori N, Huijts CM, Wildes F, Bharti S, Zhang Z, Santa-Maria CA, Tsai H, Dang CV, Stearns V, Bhujwalla ZM, Sukumar S. Targeting Glutamine Metabolism in Breast Cancer with Aminooxyacetate. Clin Cancer Res. 2015 Jul 15;21(14):3263-73. doi: 10.1158/1078-0432.CCR-14-1200. Epub 2015 Mar 26.
Key words: glutamine, breast cancer, aminooxyacetate
http://www.ncbi.nlm.nih.gov/pubmed/25813021

6. Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, Dipasquale S, Pawlik TM, Zheng L, Weiss MJ, Laheru DA, Wolfgang CL, Herman JM. The Role of Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Single-Institution Experience. Ann Surg Oncol. 2015 Jul;22(7):2352-8. doi: 10.1245/s10434-014-4274-5. Epub 2015 Jan 7.
Key words: pancreatic cancer, stereotactic, body radiation
PubMed PMID: 25564157; PubMed Central PMCID: PMC4459890.
http://www.ncbi.nlm.nih.gov/pubmed/25564157

7. Nash SH, Schenk JM, Kristal AR, Goodman PJ, Lucia MS, Parnes HL, Thompson IM, Lippman SM, Song X, Gurel B, De Marzo A, Platz EA. Association between Serum Phospholipid Fatty Acids and Intraprostatic Inflammation in the Placebo Arm of the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila). 2015 Jul;8(7):590-6. doi: 10.1158/1940-6207.CAPR-14-0398. Epub 2015 Apr 29.
Key words: inflammation, prostate cancer, phospholipid
PubMed PMID: 25926387; PubMed Central PMCID: PMC4491033.
http://www.ncbi.nlm.nih.gov/pubmed/25926387

8. Negi SS, Brown P. rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis. Oncotarget. 2015 Jul 20;6(20):18094-104.
Key words: leukemia, lymphoblastic, apoptosis
PubMed PMID: 26061708.
http://www.ncbi.nlm.nih.gov/pubmed/26061708

9. Sausen M, Phallen J, Adleff V, Jones S, Leary RJ, Barrett MT, Anagnostou V, Parpart-Li S, Murphy D, Kay Li Q, Hruban CA, Scharpf R, White JR, O'Dwyer PJ, Allen PJ, Eshleman JR, Thompson CB, Klimstra DS, Linehan DC, Maitra A, Hruban RH, Diaz LA Jr, Von Hoff DD, Johansen JS, Drebin JA, Velculescu VE. Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients. Nat Commun. 2015 Jul 7;6:7686. doi: 10.1038/ncomms8686.
Key words: pancreatic cancer, implications, genomic, alterations
http://www.ncbi.nlm.nih.gov/pubmed/26154128

10. Stanley SE, Armanios M. The short and long telomere syndromes: paired paradigms for molecular medicine. Curr Opin Genet Dev. 2015 Jul 28;33:1-9. doi: 10.1016/j.gde.2015.06.004. [Epub ahead of print] Review.
Key words: syndrome, long, telomere, molecular
http://www.ncbi.nlm.nih.gov/pubmed/26232116

1. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD,
Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP,Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD,Gupta AK, Brahmer JR. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015 Jun 20;33(18):2004-12. doi: 10.1200/JCO.2014.58.3708.
Key words: lung cancer, nivolumab
http://www.ncbi.nlm.nih.gov/pubmed/25897158

2. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30.
Key words: PD-1, mismatch, repair
http://www.ncbi.nlm.nih.gov/pubmed/26028255

3. Markowski MC, Eisenberger M, Zahurak M, Epstein JI, Paller C. Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series from Johns Hopkins Hospital. Urology. 2015 Jun 27. pii: S0090-4295(15)00597-X. doi: 10.1016/j.urology.2015.06.011. [Epub ahead of print]
Key words: prostate cancer, carcinoma, case series
http://www.ncbi.nlm.nih.gov/pubmed/26126695

4. Maughan BL, Antonarakis ES. Androgen pathway resistance in prostate cancer and therapeutic implications. Expert Opin Pharmacother. 2015 Jul;16(10):1521-37. doi: 10.1517/14656566.2015.1055249. Epub 2015 Jun 12.
Key words: prostate cancer, androgen
http://www.ncbi.nlm.nih.gov/pubmed/26067250

5. Nakazawa M, Lu C, Chen Y, Paller CJ, Carducci MA, Eisenberger MA, Luo J, Antonarakis ES. Serial blood-based analysis of AR-V7 in men with advanced prostate cancer. Ann Oncol. 2015 Jun 27. pii: mdv282. [Epub ahead of print]
Key words: prostate cancer, AR-V7
http://www.ncbi.nlm.nih.gov/pubmed/26117829

6. Patel MA, Pardoll DM. Concepts of immunotherapy for glioma. J Neurooncol. 2015 Jul;123(3):323-30. doi: 10.1007/s11060-015-1810-5. Epub 2015 Jun 13.
Key words: immunotherapy, glioma
http://www.ncbi.nlm.nih.gov/pubmed/26070552

7. Rajeshkumar NV, Dutta P, Yabuuchi S, de Wilde RF, Matrinez GV, Le A, Kamphorst JJ, Rabinowitz JD, Jain SK, Hidalgo M, Dang CV, Gillies RJ, Maitra A. Therapeutic targeting of the Warburg effect in pancreatic cancer relies on an absence of p53 function. Cancer Res. 2015 Jun 25. pii: canres.0108.2015. [Epub ahead of print]
Key words: Warburg, pancreatic cancer, p53
http://www.ncbi.nlm.nih.gov/pubmed/26113084

8. Wang Y, Springer S, Mulvey CL, Silliman N, Schaefer J, Sausen M, James N, Rettig EM, Guo T, Pickering CR, Bishop JA, Chung CH, Califano JA, Eisele DW, Fakhry C, Gourin CG, Ha PK, Kang H, Kiess A, Koch WM, Myers JN, Quon H, Richmon JD, Sidransky D, Tufano RP, Westra WH, Bettegowda C, Diaz LA Jr, Papadopoulos N, Kinzler KW, Vogelstein B, Agrawal N. Detection of somatic mutations and HPV in the saliva and plasma of patients with head and neck squamous cell carcinomas. Sci Transl Med. 2015 Jun 24;7(293):293ra104. doi: 10.1126/scitranslmed.aaa8507.
Key words: HPV, squamous, saliva, plasma
http://www.ncbi.nlm.nih.gov/pubmed/26109104

9. Woodard C, Liao G, Goodwin CR, Hu J, Xie Z, Dos Reis TF, Newman R, Rho H, Qian J, Zhu H, Hayward SD. A Screen for ERK Primed GSK-3 Substrates Identifies the p53 Inhibitor iASPP. J Virol. 2015 Jun 24. pii: JVI.01072-15. [Epub ahead of print]
Key words: ERK, p53, GSK-3
http://www.ncbi.nlm.nih.gov/pubmed/26109723

1. Beachler DC, Guo Y, Xiao W, Burk RD, Minkoff H, Strickler HD, Cranston RD, Wiley DJ, Jacobson LP, Weber KM, Margolick JB, Sugar EA, Reddy S, Gillison ML, D'Souza G. High oral HPV16 viral load predicts long-term persistence in HIV-infected and at risk HIV-uninfected individuals. J Infect Dis. 2015 May 7. pii: jiv273. [Epub ahead of print]
Key words: HPV16, viral load, HIV infection
http://www.ncbi.nlm.nih.gov/pubmed/25954049

2. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015 May 31. [Epub ahead of print]
Key words: nivolumab, docetaxel, lung cancer
http://www.ncbi.nlm.nih.gov/pubmed/26028407

3. Chen D, Nicholas J. Promotion of endoplasmic reticulum-associated degradation of pro-cathepsin d by human Herpesvirus 8-encoded viral interleukin-6. J Virol. 2015 May 27. pii: JVI.00375-15. [Epub ahead of print]
Key words: pro-cathepsin d, Herpesvirus 8, endoplasmic reticulum, interleukin-6
http://www.ncbi.nlm.nih.gov/pubmed/26018151

4. Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436-443. Review.
Key words: immunotherapy, chemotherapy, cancer
http://www.ncbi.nlm.nih.gov/pubmed/25941355

5. Joshu CE, Peskoe SB, Heaphy CM, Kenfield SA, Van Blarigan EL, Mucci LA, Giovannucci EL, Stampfer MJ, Yun G, Lee TK, Hicks JL, De Marzo AM, Meeker AK, Platz EA. Pre-diagnostic obesity and physical inactivity are associated with shorter telomere length in prostate stromal cells. Cancer Prev Res (Phila). 2015 May 19. pii: canprevres.0097.2015. [Epub ahead of print]
Key words: obesity, telomere, stromal cells, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/25990087

6. Kelly RJ, Forde PM, Elnahal SM, Forastiere AA, Rosner GL, Smith TJ. Patients and physicians can discuss costs of cancer treatment in the clinic. J Oncol Pract. 2015 May 26. pii: JOP.2015.003780. [Epub ahead of print]
Key words: patients, physicians, cancer, costs
http://www.ncbi.nlm.nih.gov/pubmed/26015459

7. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA Jr. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 May 30. [Epub ahead of print]
Key words: tumors, PD-1 blockade, mismatch-repair deficiency
http://www.ncbi.nlm.nih.gov/pubmed/26028255

8. Leech M, Morris L, Stewart M, Smith BD, Bashey A, Holland K, Solomon S, Zhang X, Carraway HE, Pratz K, Gore SD, Zeidan AM. Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy. Clin Lymphoma Myeloma Leuk. 2015 May;15(5):292-7. doi: 10.1016/j.clml.2014.11.001.
Key words: promyelocytic leukemia, arsenic trioxide, chemotherapy, anthracycline exposure
http://www.ncbi.nlm.nih.gov/pubmed/25499624

9. Zeidner JF, Foster MC, Blackford AL, Litzow MR, Morris LE, Strickland SA, Lancet JE, Bose P, Levy MY, Tibes R, Gojo I, Gocke CD, Rosner GL, Little RF, Wright JJ, Doyle LA, Smith BD, Karp JE. Randomized multicenter phase 2 study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia. Haematologica. 2015 May 28. pii: haematol.2015.125849. [Epub ahead of print]
Key words: flavorpiridol, cytarabine, mitroxantrone, acute myeloid leukemia
http://www.ncbi.nlm.nih.gov/pubmed/26022709

1. Alder JK, Barkauskas CE, Limjunyawong N, Stanley SE, Kembou F, Tuder RM, Hogan BL, Mitzner W, Armanios M. Telomere dysfunction causes alveolar stem cell failure. Proc Natl Acad Sci U S A. 2015 Apr 21;112(16):5099-104. doi: 10.1073/pnas.1504780112. Epub 2015 Apr 3.
Key words: alveolar, telomere, failure
http://www.ncbi.nlm.nih.gov/pubmed/25840590

2. Gettinger SN, Horn L, Gandhi L, Spigel DR, Antonia SJ, Rizvi NA, Powderly JD, Heist RS, Carvajal RD, Jackman DM, Sequist LV, Smith DC, Leming P, Carbone DP, Pinder-Schenck MC, Topalian SL, Hodi FS, Sosman JA, Sznol M, McDermott DF, Pardoll DM, Sankar V, Ahlers CM, Salvati M, Wigginton JM, Hellmann MD, Kollia GD, Gupta AK, Brahmer JR. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol. 2015 Apr 20. pii: JCO.2014.58.3708. [Epub ahead of print]
Key words: Nivolumab, lung cancer, survival
http://www.ncbi.nlm.nih.gov/pubmed/25897158

3. Hu C, Dadon T, Chenna V, Yabuuchi S, Bannerji R, Booher R, Strack P, Azad NA, Nelkin BD, Maitra A. Combined inhibition of cyclin-dependent kinases (dinaciclib) and AKT (MK-2206) blocks pancreatic tumor growth and metastases in patient-derived xenograft models. Mol Cancer Ther. 2015 Apr 30. pii: molcanther.0028.2015. [Epub ahead of print]
Key words: AKT, pancreatic cancer, metastases, cyclin
http://www.ncbi.nlm.nih.gov/pubmed/25931518

4. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and survival With GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Apr 20;33(12):1325-33. doi: 10.1200/JCO.2014.57.4244. Epub 2015 Jan 12.
Key words: pancreatic cancer, listeria, mesothelin
http://www.ncbi.nlm.nih.gov/pubmed/25584002

5. Pardoll DM. Distinct mechanisms of tumor resistance to NK killing: of mice and men. Immunity. 2015 Apr 21;42(4):605-6. doi: 10.1016/j.immuni.2015.04.007.
Key words: Mechanisms, tumor resistance, NK
http://www.ncbi.nlm.nih.gov/pubmed/25902479

6. Peskoe SB, Joshu CE, Rohrmann S, McGlynn KA, Nyante SJ, Bradwin G, Dobs AS, Kanarek N, Nelson WG, Platz EA. Circulating total testosterone and PSA concentrations in a nationally representative sample of men without a diagnosis of prostate cancer. Prostate. 2015 Apr 28. doi: 10.1002/pros.22998. [Epub ahead of print]
Key words: testosterone, prostate cancer, PSA
http://www.ncbi.nlm.nih.gov/pubmed/25919471

7. Rao AD, Sugar EA, Barrett N, Mahesh M, Arceci RJ. The utility of computed tomography in the management of fever and neutropenia in pediatric oncology. Pediatr Blood Cancer. 2015 Apr 30. doi: 10.1002/pbc.25561. [Epub ahead of print]
Key words: neutropenia, pediatric oncology, tomography
http://www.ncbi.nlm.nih.gov/pubmed/25929242

8. Strowd RE 3rd, Abuali IA, Grossman SA. Objective cerebrospinal fluid response to intraventricular rituximab in indolent CNS lymphoma. CNS Oncol. 2015 May;4(3):131-5. doi: 10.2217/cns.15.3. Epub 2015 Apr 23.
Key words: lymphoma, rituximab, crerebrospinal
http://www.ncbi.nlm.nih.gov/pubmed/25905905

9. Wang J, Reiss Binder K, Khatri R, Jaffee E, Laheru D. Immune therapy in GI malignancies: a review. J Clin Oncol. 2015 Apr 27. pii: JCO.2015.60.7879. [Epub ahead of print] Review. PubMed PMID: 25918295.
Key words: GI, immune therapy
http://www.ncbi.nlm.nih.gov/pubmed/25918295

1. Culton DA, McCray SK, Park M, Roberts JC, Li N, Zedek DC, Anhalt GJ, Cowley D, Liu Z, Diaz LA. Mucosal pemphigus vulgaris Anti-Dsg3 IgG are pathogenic to the oral mucosa of humanized Dsg3 mice. J Invest Dermatol. 2015 Feb 19. doi: 10.1038/jid.2015.54. [Epub ahead of print]
Key words: oral mucosa, Dsg3, humanized
http://www.ncbi.nlm.nih.gov/pubmed/25695683

2. Isaacs JT. Lessons learned about prostatic transformation from the age-related methylation of 5?-reductase type 2 gene. Am J Pathol. 2015 Mar;185(3):614-6. doi: 10.1016/j.ajpath.2015.01.001. Epub 2015 Feb 17.
Key words: methylation, transformation, prostate cancer
http://www.ncbi.nlm.nih.gov/pubmed/25700984

3. Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, Jaffee E. Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res. 2015 Feb 17. [Epub ahead of print]
Key words: plasmacytoid, antitumor, galectin-3
http://www.ncbi.nlm.nih.gov/pubmed/25691328

4. Kulac I, Haffner MC, Yegnasubramanian S, Epstein JI, De Marzo AM. Should Gleason 6 be labeled as cancer? Curr Opin Urol. 2015 Feb 27. [Epub ahead of print]
Key words: gleason 6, cancer
http://www.ncbi.nlm.nih.gov/pubmed/25730327

5. Weingart MF, Roth JJ, Hutt-Cabezas M, Busse TM, Kaur H, Price A, Maynard R, Rubens J, Taylor I, Mao XG, Xu J, Kuwahara Y, Allen SJ, Erdreich-Epstein A, Weissman BE, Orr BA, Eberhart CG, Biegel JA, Raabe EH. Disrupting LIN28 in atypical teratoid rhabdoid tumors reveals the importance of the mitogen activated protein kinase pathway as a therapeutic target. Oncotarget. 2015 Feb 20;6(5):3165-77.
Key words: teratoid, mitogen, kinase, rhabdoid
http://www.ncbi.nlm.nih.gov/pubmed/25638158

1. Afsari B, Fertig EJ, Geman D, Marchionni L. switchBox: an R package for k Top Scoring Pairs classifier development. Bioinformatics. 2015 Jan 15;31(2):273-4. doi: 10.1093/bioinformatics/btu622. Epub 2014 Sep 26.
Key words: switchbox, classifier, development
http://www.ncbi.nlm.nih.gov/pubmed/25262153

2. Boleij A, Hechenbleikner EM, Goodwin AC, Badani R, Stein EM, Lazarev MG, Ellis B, Carroll KC, Albesiano E, Wick EC, Platz EA, Pardoll DM, Sears CL. The Bacteroides fragilis toxin gene is prevalent in the colon mucosa of colorectal cancer patients. Clin Infect Dis. 2015 Jan 15;60(2):208-15. doi: 10.1093/cid/ciu787..
Key words: colorectal cancer, mucosa, bacteroides
http://www.ncbi.nlm.nih.gov/pubmed/25305284

3. Chu NJ, Armstrong TD, Jaffee EM. Nonviral oncogenic antigens and the inflammatory signals driving early cancer development as targets for cancer immunoprevention. Clin Cancer Res. 2015 Jan 26. pii: clincanres.1186.2014. [Epub ahead of print]
Key words: immunoprevention, antigens, inflammatory, signals
http://www.ncbi.nlm.nih.gov/pubmed/25623216

4. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol. 2015 Jan 12. pii: JCO.2014.57.4244. [Epub ahead of print]
Key words: listeria, pancreatic cancer, mesothelin
http://www.ncbi.nlm.nih.gov/pubmed/25584002

5. Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 adjuvant breast cancer aromatase inhibitor trial. J Clin Oncol. 2015 Jan 20;33(3):265-71. doi: 10.1200/JCO.2014.57.6926.
Key words: breast cancer, muscoskeletal, aromatase
http://www.ncbi.nlm.nih.gov/pubmed/25512454

6. Schweizer MT, Antonarakis ES, Wang H, Ajiboye AS, Spitz A, Cao H, Luo J, Haffner MC, Yegnasubramanian S, Carducci MA, Eisenberger MA, Isaacs JT, Denmeade SR. Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: Results from a pilot clinical study. Sci Transl Med. 2015 Jan 7;7(269):269ra2. doi: 10.1126/scitranslmed.3010563.
Key words: prostate cancer, androgen therapy, asymptomatic
http://www.ncbi.nlm.nih.gov/pubmed/25568070

7. Wilky BA, Rudek MA, Ahmed S, Laheru DA, Cosgrove D, Donehower RC, Nelkin B, Ball D, Doyle LA, Chen H, Ye X, Bigley G, Womack C, Azad NS. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours. Br J Cancer. 2015 Jan 6;112(1):24-31. doi: 10.1038/bjc.2014.515.
Key words: cituxumumab, selumetinib, inhibitor
http://www.ncbi.nlm.nih.gov/pubmed/25268371

1. Connolly RM, Leal JP, Goetz MP, Zhang Z, Zhou XC, Jacobs LK, Mhlanga J, O JH, Carpenter J, Storniolo AM, Watkins S, Fetting JH, Miller RS, Sideras K, Jeter SC, Walsh B, Powers P, Zorzi J, Boughey JC, Davidson NE, Carey LA, Wolff AC, Khouri N, Gabrielson E, Wahl RL, Stearns V. TBCRC 008: Early change in 18F-FDG uptake on PET predicts response to preoperative systemic therapy in human epidermal growth factor receptor 2-negative primary operable breast cancer. J Nucl Med. 2015 Jan;56(1):31-7. doi: 10.2967/jnumed.114.144741.
Key words: breast cancer, PET, epidermal
http://www.ncbi.nlm.nih.gov/pubmed/25476537

2. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS. Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477.
Key words: cyclophosphamide, myeloablative, GVHD
http://www.ncbi.nlm.nih.gov/pubmed/25316679

3. LeBeau AM, Denmeade SR. Protease-activated pore-forming peptides for the treatment and imaging of prostate cancer. Mol Cancer Ther. 2014 Dec 23. pii: molcanther.0744.2014. [Epub ahead of print]
Key words: prostate cancer, peptides, imaging
http://www.ncbi.nlm.nih.gov/pubmed/25537662

4. Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17606-11. doi: 10.1073/pnas.1408650111.
Key words: estrogen, tamoxifen, breast cancer
http://www.ncbi.nlm.nih.gov/pubmed/25422431

5. Pollizzi KN, Powell JD. Regulation of T cells by mTOR: the known knowns and the known unknowns. Trends Immunol. 2015 Jan;36(1):13-20. doi: 10.1016/j.it.2014.11.005. Epub 2014 Dec 16. Review.
Key words: regulation, mTOR
http://www.ncbi.nlm.nih.gov/pubmed/25522665

6. Sharabi AB, Nirschl CJ, Kochel CM, Nirschl TR, Francica BJ, Velarde E, DeWeese TL, Drake CG. Stereotactic radiation therapy augments antigen-specific PD-1 mediated anti-tumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res. 2014 Dec 19. pii: canimm.0196.2014. [Epub ahead of print]
Key words: antigen, stereotactic, radiation
http://www.ncbi.nlm.nih.gov/pubmed/25527358

7. Stearns V, Chapman JA, Ma CX, Ellis MJ, Ingle JN, Pritchard KI, Budd GT, Rabaglio M, Sledge GW, Le Maitre A, Kundapur J, Liedke PE, Shepherd LE, Goss PE. Treatment-associated musculoskeletal and vasomotor symptoms and relapse-free survival in the NCIC CTG MA.27 Adjuvant Breast Cancer Aromatase Inhibitor Trial. J Clin Oncol. 2014 Dec 15. pii: JCO.2014.57.6926. [Epub ahead of print]
Key words: breast cancer, vasomotor, musculoskeletal

http://www.ncbi.nlm.nih.gov/pubmed/25512454

8. Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):118-23. doi: 10.1073/pnas.1421839112. Epub 2014 Dec 22.
Key words: lung cancer, colorectal cancer, driver gene
http://www.ncbi.nlm.nih.gov/pubmed/25535351

9. Wolff AC, Blackford AL, Visvanathan K, Rugo HS, Moy B, Goldstein LJ, Stockerl-Goldstein K, Neumayer L, Langbaum TS, Theriault RL, Hughes ME, Weeks JC, Karp JE. Risk of marrow neoplasms after adjuvant breast cancer therapy: The National Comprehensive Cancer Network Experience. J Clin Oncol. 2014 Dec 22. pii: JCO.2013.54.6119. [Epub ahead of print]
Key words: breast cancer, neoplasms, marrow
http://www.ncbi.nlm.nih.gov/pubmed/25534386

1. Bolaños-Meade J, Logan BR, Alousi AM, Antin JH, Barowski K, Carter SL, Goldstein SC, Hexner EO, Horowitz MM, Lee SJ, Levine JE, MacMillan ML, Martin PJ, Mendizabal AM, Nakamura R, Pasquini MC, Weisdorf DJ, Westervelt P, Ho VT. Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802. Blood. 2014 Nov 20;124(22):3221-7. doi: 10.1182/blood-2014-06-577023.
Key words: mofetil, mycophenolate, steroids
http://www.ncbi.nlm.nih.gov/pubmed/25170121

2. Han L, Diehl A, Nguyen NK, Korangath P, Teo W, Cho S, Kominsky S, Huso DL, Feigenbaum L, Rein A, Argani P, Landberg G, Gessler M, Sukumar S. The Notch Pathway Inhibits TGF? Signaling in Breast Cancer through HEYL-Mediated Crosstalk. Cancer Res. 2014 Nov 15;74(22):6509-18. doi: 10.1158/0008-5472.CAN-14-0816. Epub 2014 Sep 12.
Key words: breast cancer, notch, crosstalk
http://www.ncbi.nlm.nih.gov/pubmed/25217524

3. Kang H, Kiess A, Chung CH. Emerging biomarkers in head and neck cancer in the era of genomics. Nat Rev Clin Oncol. 2014 Nov 18. doi: 10.1038/nrclinonc.2014.192. [Epub ahead of print] Review.
Key words: biomarkers, genomic, emerging
http://www.ncbi.nlm.nih.gov/pubmed/25403939

4. Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, Erlanger B, Argani P, Hurley PJ, Lauring J, Park BH. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proc Natl Acad Sci U S A. 2014 Nov 24. pii: 201408650. [Epub ahead of print]
Key words: breast cancer, tamoxifen, estrogen, overexpression
http://www.ncbi.nlm.nih.gov/pubmed/25422431

5. Galanis A, Levis M. Inhibition of c-Kit by tyrosine kinase inhibitors. Haematologica. 2014 Nov 25. pii: haematol.2014.117028. [Epub ahead of print]
Key words: kinase, c-Kit, inhibitor
http://www.ncbi.nlm.nih.gov/pubmed/25425690

6. Ghosh S, Bhunia AK, Paun BC, Gilbert SF, Dhru U, Patel K, Kern SE. Genome Annotation by Shotgun Inactivation of a Native Gene in Hemizygous Cells: Application to BRCA2 with Implication of Hypomorphic Variants. Hum Mutat. 2014 Nov 29. doi: 10.1002/humu.22736. [Epub ahead of print]
Key words: hypomorphic, shotgun, BRCA2
http://www.ncbi.nlm.nih.gov/pubmed/25451944

7. Vendetti FP, Topper M, Huang P, Dobromilskaya I, Easwaran H, Wrangle J, Baylin SB, Poirier JT, Rudin CM. Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget. 2014 Nov 25. [Epub ahead of print]
Key words: entinostat, lung cancer, cytotoxic
http://www.ncbi.nlm.nih.gov/pubmed/25474141

1. Dluzniewski PJ, Xu J, Ruczinski I, Isaacs WB, Platz EA. Polymorphisms influencing prostate specific antigen concentration may bias genome-wide association studies on prostate cancer. Cancer Epidemiol Biomarkers Prev. 2014 Oct 28. pii: cebp.0863.2014. [Epub ahead of print]
Key words: polymorphisms, prostate cancer, bias, antigen
http://www.ncbi.nlm.nih.gov/pubmed/25352524

2. Drake CG, Sharma P, Gerritsen W. Metastatic castration-resistant prostate cancer: new therapies, novel combination strategies and implications for immunotherapy. Oncogene. 2014 Oct 23;33(43):5053-5064. doi: 10.1038/onc.2013.497. Epub 2013 Nov 25. Review.
Key words: immunotherapy, prostate cancer, novel combination
http://www.ncbi.nlm.nih.gov/pubmed/24276248

3. Huang TC, Renuse S, Pinto S, Kumar P, Yang Y, Chaerkady R, Godsey B, Mendell JT, Halushka MK, Civin CI, Marchionni L, Pandey A. Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst. 2014 Oct 30. [Epub ahead of print]
Key words: omics, miR-145
http://www.ncbi.nlm.nih.gov/pubmed/25354783

4. Gojo I, Karp JE. new strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine. Clin Cancer Res. 2014 Oct 16. pii: clincanres.0900.2014. [Epub ahead of print]
Key words: leukemia, strategies, personalized
http://www.ncbi.nlm.nih.gov/pubmed/25324141

5. Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L. Post-transplantation cyclophosphamide as single-agent GVHD prophylaxis after myeloablative conditioning and HLA-matched allografting for acute leukemias and myelodysplastic syndrome. Blood. 2014 Oct 14. pii: blood-2014-07-587477. [Epub ahead of print]
Key words: leukemia, myelodysplastic, GVHD
http://www.ncbi.nlm.nih.gov/pubmed/25316679

6. Kanakry CG, Luznik L. Are alternative donors really still "alternative?" Biol Blood Marrow Transplant. 2014 Oct;20(10):1463-4. doi: 10.1016/j.bbmt.2014.07.029. Epub 2014 Jul 31.
Key words: alternative, donors
http://www.ncbi.nlm.nih.gov/pubmed/25087900

7. Lavorgna A, Harhaj EW. Regulation of HTLV-1 tax stability, cellular trafficking and NF-?B activation by the ubiquitin-proteasome pathway. Viruses. 2014 Oct 23;6(10):3925-3943. Review.
Key words: viruses, activation, HTLV-1
http://www.ncbi.nlm.nih.gov/pubmed/25341660

8. Llosa NJ, Cruise M, Tam A, Wick EC, Hechenbleikner EM, Taube JM, Blosser L, Fan H, Wang H, Luber B, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 2014 Oct 30. pii: CD-14-0863. [Epub ahead of print]
Key words: microsatellite, colon cancer, checkpoints
http://www.ncbi.nlm.nih.gov/pubmed/25358689

9. Reiss KA, Herman JM, Zahurak ML, Brade A, Dawson L, Scardina A, Joffe C, Petito E, Hacker-Prietz A, Kinders R, Wang L, Chen A, Temkin SM, Horiba N, Siu LL, Azad NA. A Phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy in patients with advanced solid malignancies and peritoneal carcinomatosis. Clin Cancer Res. 2014 Oct 29. pii: clincanres.1552.2014. [Epub ahead of print]
Key words: carcinomatosis, abdominal, veliparib, radiation therapy
http://www.ncbi.nlm.nih.gov/pubmed/25355929

10. Sison EA, Magoon D, Li L, Annesley CE, Rau RE, Small D, Brown P. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition. Oncotarget. 2014 Oct 15;5(19):8947-58.
Key words: leukemia, resistance, CXCR4
http://www.ncbi.nlm.nih.gov/pubmed/25333254

1. Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L. The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy. HPB (Oxford). 2014 Sep 23. doi: 10.1111/hpb.12334. [Epub ahead of print]
Key words: stroma, pancreatic cancer, prognostic
http://www.ncbi.nlm.nih.gov/pubmed/25250696

2. Ganguly S, Ross DB, Panoskaltsis-Mortari A, Kanakry CG, Blazar BR, Levy RB, Luznik L. Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice. Blood. 2014 Sep 25;124(13):2131-41. doi: 10.1182/blood-2013-10-525873.
Key words: Foxp3, protection, GVHD
http://www.ncbi.nlm.nih.gov/pubmed/25139358

3. Jones S, Stransky N, McCord CL, Cerami E, Lagowski J, Kelly D, Angiuoli SV, Sausen M, Kann L, Shukla M, Makar R, Wood LD, Diaz LA Jr, Lengauer C, Velculescu VE. Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes. Nat Commun. 2014 Sep 19;5:5006. doi: 10.1038/ncomms6006.
Key words: chromatin, gynaecologic, mutations
http://www.ncbi.nlm.nih.gov/pubmed/25233892

4. Kanakry CG, O'Donnell PV, Furlong T, de Lima MJ, Wei W, Medeot M, Mielcarek M, Champlin RE, Jones RJ, Thall PF, Andersson BS, Luznik L. Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Sep 29. pii: JCO.2013.54.0625. [Epub ahead of print]
Key words: bone marrow, cyclophosphamide, transplantation, allogeneic
http://www.ncbi.nlm.nih.gov/pubmed/25267759

5. Konig H, Levis M. Targeting FLT3 to treat leukemia. Expert Opin Ther Targets. 2014 Sep 18:1-18. [Epub ahead of print]
Key words: leukemia, treat, FLT3
http://www.ncbi.nlm.nih.gov/pubmed/25231999

6. Kumar A, Le DT. Hepatocellular carcinoma regression after cessation of immunosuppressive therapy. J Clin Oncol. 2014 Sep 22. pii: JCO.2013.51.4067. [Epub ahead of print]
Key words: regression, hepatocellular, carcinoma
http://www.ncbi.nlm.nih.gov/pubmed/2524544

7. Lopez DS, Peskoe SB, Tsilidis KK, Hoffman-Bolton J, Helzlsouer KJ, Isaacs WB, Smith MW, Platz EA. Association of variants in genes related to the immune response and obesity with BPH in CLUE II. Prostate Cancer Prostatic Dis. 2014 Sep 16. doi: 10.1038/pcan.2014.36. [Epub ahead of print]
Key words: prostate cancer, obesity, variants, genes
http://www.ncbi.nlm.nih.gov/pubmed/25224558

8. Richman LK, Zong JC, Latimer EM, Lock J, Fleischer R, Heaggans SY, Hayward GS. Elephant endotheliotropic herpesviruses EEHV1A, EEHV1B and EEHV2 from cases of hemorrhagic disease are highly diverged from other mammalian herpesviruses and may form a new subfamily. J Virol. 2014 Sep 17. pii: JVI.01673-14. [Epub ahead of print]
Key words: endotheliotropic, elephant, diverged, subfamily
http://www.ncbi.nlm.nih.gov/pubmed/25231303

9. Soares KC, Foley K, Olino K, Leubner A, Mayo SC, Jain A, Jaffee E, Schulick RD, Yoshimura K, Edil B, Zheng L. A preclinical murine model of hepatic metastases. J Vis Exp. 2014 Sep 27;(91). doi: 10.3791/51677.
Key words: hepatic, murine, metastases
http://www.ncbi.nlm.nih.gov/pubmed/25285458

10. Zong JC, Latimer EM, Long SY, Richman LK, Heaggans SY, Hayward GS. Comparative genome analysis of four elephant endotheliotropic herpesviruses EEHV3, EEHV4, EEHV5 and EEHV6 from cases of hemorrhagic disease or viremia. J Virol. 2014 Sep 17. pii: JVI.01675-14. [Epub ahead of print]
Key words: elephant, viremia, genome, analysis
http://www.ncbi.nlm.nih.gov/pubmed/25231309

Return to top of Publications - Oncology Archives


Search Publications
 
   
October 2017 articles:
Changes to NIH-funded Human Subjects Research
Free Resources for Longitudinal Clinical Research Studies
New Fee Schedule for Commercially Funded Studies
NIH requirement for Single IRB (sIRB)
JHM IRB Reliance Requests
Sharing Partnership for Innovative Research in Translation
Johns Hopkins Institute for Clinical and Translational Research
Johns Hopkins Research Network
 
Visit Animal Care and Use Committee Website
Current Classes
"Interinstitutional Assurance" Agreement
Health, Safety, and Environment (HSE) presents: Safety in Research Updates
Understanding, Preventing, and Managing Immunotherapy-related Adverse Events (irAEs) Associated with Checkpoint Inhibition for Melanoma and Other Cancers
AHA Institute for Precision Cardiovascular Medicine
National Science Foundation (NSF) Major Research Instrumentation Program (MRI) Instrument Acquisition or Development
Camille Dreyfus Teacher-Scholar Award
Michael J. Fox Foundation (MJFF) Challenge
NIH Video Tutorials on How to Apply for Grants
NIH Policy: Foreign Components Added to a Grant to a Domestic or Foreign Organization

This Month's Departmental Listings

Upcoming Deadlines for October, November and December

October Events at the Genetic Resources Core Facility
       

 

JHM AppointmentsEmployment @ JHM | Finding a Doctor | Disclaimer | Maps & Directions | Contact JHM 

 

                                                                                                                                                           The Web Center